Zura Bio Limited
ZURAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 12, 2026 | Guggenheim | Yatin Suneja | $20.00(+260%) | $5.56 | TheFly |
| Feb 9, 2026 | Wedbush | $15.00(+150%) | $6.01 | TheFly | |
| Apr 3, 2025 | H.C. Wainwright | Mitchell Kapoor | $3.00(+175%) | $1.09 | TheFly |
| Nov 8, 2024 | Guggenheim | Yatin Suneja | $15.00(+228%) | $4.58 | StreetInsider |
| Sep 5, 2024 | H.C. Wainwright | Mitchell Kapoor | $5.00(+27%) | $3.95 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wedbush | maintain | Outperform | Aug 12, 2026 |
| Guggenheim | maintain | Buy | Aug 12, 2026 |
| Wedbush | maintain | Outperform | Jul 1, 2026 |
| Chardan Capital | maintain | Buy | Mar 23, 2026 |
| Oppenheimer | maintain | Outperform | Mar 20, 2026 |
| Chardan Capital | maintain | Buy | Nov 14, 2025 |
| Chardan Capital | maintain | Buy | Sep 30, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Aug 19, 2025 |
| Oppenheimer | maintain | Outperform | Aug 15, 2025 |
| Chardan Capital | maintain | Buy | Aug 15, 2025 |
| Oppenheimer | maintain | Outperform | May 9, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Apr 3, 2025 |
| Oppenheimer | maintain | Outperform | Mar 26, 2025 |
| Guggenheim | maintain | Buy | Mar 26, 2025 |
| Chardan Capital | maintain | Buy | Mar 26, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Dec 24, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Dec 11, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Nov 18, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Nov 11, 2024 |
| Chardan Capital | maintain | Buy | Nov 8, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Oct 21, 2024 |
| Piper Sandler | maintain | Overweight | Sep 19, 2024 |
| Oppenheimer | maintain | Outperform | May 10, 2024 |
| Oppenheimer | maintain | Outperform | Apr 1, 2024 |
| Raymond James | maintain | Strong Buy | Aug 15, 2023 |
Earnings History
Next report: Mar 18, 2027 · EPS est. $-0.19| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 27, 2026 | $-0.20 | $-0.20 | — | — |
| Aug 11, 2026 | $-0.21 | $-0.19 | — | — |
| May 7, 2026 | $-0.22 | $-0.17 | — | — |
| Mar 19, 2026 | $-0.49 | $-0.18 | — | — |
| Nov 13, 2025 | $-0.21 | $-0.19 | — | — |
| Aug 14, 2025 | $-0.17 | $-0.19 | — | — |
| May 8, 2025 | $-0.19 | $-0.17 | — | — |
| Mar 25, 2025 | $-0.14 | $-0.16 | — | — |
News
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on October 26, 2026, the Company granted inducement awards consisting of options to purchase up to 250,200 Class A Ordinary Shares (the “Options”) to five newly hired employees. These awa.
[url="]Zura Bio Limited[/url] (Nasdaq: ZURA) (âZuraâ), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the third quarter ended September 30, 2026, and provided recent corporate updates. “Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited.
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference: Cantor Global Healthcare Conference Location: New York, NY Fireside chat: Wednesday, September 9, 2026, at 9.
Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Profitability This table compares Soligenix and Zura Bio's
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These.
Zura Bio Limited (Nasdaq: ZURA) (âZuraâ), a clinicalâstage biotechnology company developing novel and differentiated medicines to meaningfully improve the
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “The second quarter was marked by strong execution across our tibulizumab programs, with enrollment now com.